SAN DIEGO, Sept. 5, 2019 /PRNewswire/ -- NuVasive, Inc.
(NASDAQ: NUVA), the leader in spine technology innovation, focused
on transforming spine surgery with minimally disruptive,
procedurally integrated solutions, today announced the commercial
launch of Modulus® Cervical, a porous titanium interbody implant
for cervical applications. The availability of Modulus Cervical
expands the Company's Advanced Materials Science™ (AMS)
portfolio to include both Porous PEEK™ and porous titanium
offerings for anterior cervical discectomy and fusion (ACDF)
techniques, a commonly performed surgery to address cervical disc
degeneration or spinal instability.
NuVasive's Modulus offerings are part of the Company's AMS
portfolio that represent the future of porous implant technologies.
Adhering to the core principles of AMS — surface, structure and
imaging — Modulus is intelligently designed to combine the inherent
benefits of porosity with the advantageous material properties of
titanium.
"Modulus Cervical provides the structural benefits of titanium,
an imaging advantage closer to radiolucent materials and a lattice
structure that allows for bone in-growth," said Dr. Michael W. Groff, MD, neurosurgeon at Brigham
& Woman's Hospital. "These characteristics, combined with the
implant's porous surface technology, are unmatched compared to
other cervical interbodies on the market."
Traditional PEEK and titanium implants are limited by the
materials from which they are created, which often result in
surgeons being forced to make compromises when selecting a spinal
implant - a sacrifice of radiolucency for durability or
favorable osteogenic properties and a desired stiffness similar to
bone. As observed in animal studies, Modulus implants are uniquely
designed to provide a favorable environment for bone in-growth,
while mimicking a stiffness that is similar to bone and allowing
for enhanced visualization on a variety of imaging modalities.
"NuVasive's expanded AMS portfolio for cervical applications
provides surgeons with additional solutions to select the right
material for their patient," said Matt
Link, president of NuVasive. "Our delivery of a
best-in-class implant for this space is a direct reflection of our
efforts to provide better patient outcomes through continued
expansion of our cervical portfolio."
About NuVasive
NuVasive, Inc. (NASDAQ:
NUVA) is the leader in spine technology innovation, focused on
transforming spine surgery and beyond with minimally disruptive,
procedurally integrated solutions designed to deliver reproducible
and clinically-proven surgical outcomes. The Company's portfolio
includes access instruments, implantable hardware, biologics,
software systems for surgical planning, navigation and imaging
solutions, magnetically adjustable implant systems for spine and
orthopedics, and intraoperative monitoring service offerings. With
more than $1 billion in revenues,
NuVasive has approximately 2,600 employees and operates in more
than 50 countries serving surgeons, hospitals and patients. For
more information, please visit www.nuvasive.com.
Forward-Looking Statements
NuVasive cautions
you that statements included in this news release that are not a
description of historical facts are forward-looking statements that
involve risks, uncertainties, assumptions and other factors which,
if they do not materialize or prove correct, could cause NuVasive's
results to differ materially from historical results or those
expressed or implied by such forward-looking statements. The
potential risks and uncertainties which contribute to the uncertain
nature of these statements include, among others, risks associated
with acceptance of the Company's surgical products and procedures
by spine surgeons, development and acceptance of new products or
product enhancements, clinical and statistical verification of the
benefits achieved via the use of NuVasive's products (including the
iGA® platform), the Company's ability to effectually manage
inventory as it continues to release new products, its ability to
recruit and retain management and key personnel, and the other
risks and uncertainties described in NuVasive's news releases and
periodic filings with the Securities and Exchange Commission.
NuVasive's public filings with the Securities and Exchange
Commission are available at www.sec.gov. NuVasive assumes no
obligation to update any forward-looking statement to reflect
events or circumstances arising after the date on which it was
made.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/nuvasive-expands-cervical-advanced-materials-science-portfolio-with-launch-of-porous-titanium-implant-300911844.html
SOURCE NuVasive, Inc.